{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:39:25Z","timestamp":1787017165874,"version":"build-2736575974"},"reference-count":43,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,6,14]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) therapy for myopia choroidal neovascularisation (CNV), and to compare the efficacy of two different anti-VEGF retreatment criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov were searched from inception to 31 July 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection<\/jats:title>\n                    <jats:p>Randomised controlled trials (RCTs) comparing anti-VEGF with sham, photodynamic therapy (PDT) or PDT combination therapy in patients with myopia CNV were reviewed and selected. RCTs comparing visual acuity (VA) stabilisation or disease activity as anti-VEGF retreatment criteria were also included in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Two reviewers independently conducted data extraction and quality assessment. We used a random-effects model for all analyses. Primary outcomes included best-corrected visual acuity (BCVA) and central foveal thickness. Secondary outcomes included number of patients who gained more than three lines in BCVA, number of anti-VEGF injections and ocular adverse event (AE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven RCTs involving 1007 patients were included. Compared with sham and PDT therapy, anti-VEGF therapy achieved better BCVA gains of \u22120.28 logMAR (95% CI \u22120.36 to \u22120.20, p&lt;0.00001) and \u22120.14 logMAR (95% CI \u22120.17 to \u22120.10, p&lt;0.00001), respectively. Both ranibizumab and bevacizumab improved patients\u2019 vision better than PDT therapy and no definitive increased risk of ocular AE was observed. Analysis of two small RCTs showed that PDT combination therapy had similar visual improvement and needed fewer anti-VEGF injections compared with anti-VEGF monotherapy (weighted mean difference (WMD)=1.30; 95% CI 1.24 to 1.37, p&lt;0.00001). Anti-VEGF retreatment guided by disease activity criteria resulted in comparable visual improvement and reduced anti-VEGF injections compared with retreatment guided by VA stabilisation (WMD=0.83; 95% CI 0.42 to 1.25, p&lt;0.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anti-VEGF therapy is effective and well-tolerated for myopia CNV patients. Anti-VEGF retreatment guided by disease activity criteria can achieve comparable efficacy and potentially reduce anti-VEGF injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42021292806.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-067921","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T12:50:45Z","timestamp":1689857445000},"page":"e067921","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of antivascular endothelial growth factor treatment for myopia choroidal neovascularisation: a systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1188-8637","authenticated-orcid":false,"given":"Liming","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"2025120618354399000_13.7.e067921.1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25957"},{"key":"2025120618354399000_13.7.e067921.2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14740338.2021.1952979","article-title":"Safety review of anti-VEGF therapy in patients with myopic Choroidal neovascularization","volume":"21","author":"Ng","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"2025120618354399000_13.7.e067921.3","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305131"},{"key":"2025120618354399000_13.7.e067921.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.08.010"},{"key":"2025120618354399000_13.7.e067921.5","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1080\/14712598.2021.1830969","article-title":"Ranibizumab for myopic Choroidal neovascularization","volume":"20","author":"Ng","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2025120618354399000_13.7.e067921.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(03)00461-5"},{"key":"2025120618354399000_13.7.e067921.7","doi-asserted-by":"crossref","unstructured":"Virgili G , Menchini F . Laser Photocoagulation for Choroidal Neovascularisation in pathologic myopia. Cochrane Database Syst Rev 2005:CD004765. doi:10.1002\/14651858.CD004765.pub2","DOI":"10.1002\/14651858.CD004765.pub2"},{"key":"2025120618354399000_13.7.e067921.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00544-9"},{"key":"2025120618354399000_13.7.e067921.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01998-X"},{"key":"2025120618354399000_13.7.e067921.10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archopht.118.3.344","article-title":"Subretinal surgery for Choroidal neovascularization in patients with high myopia","volume":"118","author":"Uemura","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"2025120618354399000_13.7.e067921.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.06.046"},{"key":"2025120618354399000_13.7.e067921.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.10.005"},{"key":"2025120618354399000_13.7.e067921.13","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182411cee"},{"key":"2025120618354399000_13.7.e067921.14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2174\/1389450122999210128180725","article-title":"Anti-VEGF therapy in myopic CNV","volume":"22","author":"Toto","year":"2021","journal-title":"Curr Drug Targets"},{"key":"2025120618354399000_13.7.e067921.15","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014905","article-title":"Comparison of intravitreal Bevacizumab and Ranibizumab used for myopic Choroidal neovascularization: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials","volume":"98","author":"Hu","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025120618354399000_13.7.e067921.16","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000240121.28034.c3"},{"key":"2025120618354399000_13.7.e067921.17","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1177\/1120672120963455","article-title":"Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic Choroidal neovascularization","volume":"31","author":"Corazza","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"2025120618354399000_13.7.e067921.18","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31827d260a"},{"key":"2025120618354399000_13.7.e067921.19","article-title":"Anti-vascular endothelial growth factor for Choroidal Neovascularisation in people with pathological myopia","volume":"12","author":"Zhu","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025120618354399000_13.7.e067921.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.04.028"},{"key":"2025120618354399000_13.7.e067921.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.10.023"},{"key":"2025120618354399000_13.7.e067921.22","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1097\/IAE.0000000000002292","article-title":"Ranibizumab versus Verteporfin Photodynamic therapy in Asian patients with myopic Choroidal neovascularization: BRILLIANCE, a 12-month, randomized, double-masked study","volume":"39","author":"Chen","year":"2019","journal-title":"Retina"},{"key":"2025120618354399000_13.7.e067921.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and Exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025120618354399000_13.7.e067921.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025120618354399000_13.7.e067921.25","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d87e04"},{"key":"2025120618354399000_13.7.e067921.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2004.01.014"},{"key":"2025120618354399000_13.7.e067921.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025120618354399000_13.7.e067921.28","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal Aflibercept injection in patients with myopic Choroidal neovascularization: the MYRROR study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"2025120618354399000_13.7.e067921.29","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.408"},{"key":"2025120618354399000_13.7.e067921.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.03.006"},{"key":"2025120618354399000_13.7.e067921.31","first-page":"335","article-title":"Combined therapy with Bevacizumab and Photodynamic therapy for myopic Choroidal neovascularization: a one-year follow-up controlled study","volume":"7","author":"Saviano","year":"2014","journal-title":"Int J Ophthalmol"},{"key":"2025120618354399000_13.7.e067921.32","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00417-016-3498-4","article-title":"Reduced-Fluence Verteporfin Photodynamic therapy plus Ranibizumab for Choroidal neovascularization in pathologic myopia","volume":"255","author":"Rinaldi","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2025120618354399000_13.7.e067921.33","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1097\/IAE.0000000000001858","article-title":"Long-term outcomes of Ranibizumab treatment of myopic Choroidal neovascularization in East-Asian patients from the RADIANCE study","volume":"38","author":"Tan","year":"2018","journal-title":"Retina"},{"key":"2025120618354399000_13.7.e067921.34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/cxo.12009","article-title":"Macular hole after intravitreal Bevacizumab injection for Choroidal Neovascularisation","volume":"97","author":"Tufan","year":"2014","journal-title":"Clin Exp Optom"},{"key":"2025120618354399000_13.7.e067921.35","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/IAE.0000000000001384","article-title":"Choroidal thickness and Chorioretinal atrophy in myopic Choroidal neovascularization with anti-vascular endothelial growth factor therapy","volume":"37","author":"Lee","year":"2017","journal-title":"Retina"},{"key":"2025120618354399000_13.7.e067921.36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41433-019-0516-x","article-title":"Progression and new onset of macular Retinoschisis in myopic Choroidal neovascularization eyes after Conbercept therapy: a post-hoc analysis","volume":"34","author":"Zhou","year":"2020","journal-title":"Eye (Lond)"},{"key":"2025120618354399000_13.7.e067921.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.06.010"},{"key":"2025120618354399000_13.7.e067921.38","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1097\/IAE.0000000000001436","article-title":"Factors influencing visual acuity in patients receiving anti-vascular endothelial growth factor for myopic Choroidal neovascularization","volume":"37","author":"Iacono","year":"2017","journal-title":"Retina"},{"key":"2025120618354399000_13.7.e067921.39","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/ceo.13507","article-title":"Two different initial treatment regimens of Ranibizumab in myopic Choroidal neovascularization: 12-month results from a randomized controlled study","volume":"47","author":"Li","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"key":"2025120618354399000_13.7.e067921.40","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1097\/IAE.0000000000000610","article-title":"Factors influencing need for Retreatment and long-term visual outcome after intravitreal Bevacizumab for myopic Choroidal neovascularization","volume":"35","author":"Ng","year":"2015","journal-title":"Retina"},{"key":"2025120618354399000_13.7.e067921.41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.oret.2018.08.002","article-title":"A multinational comparison of anti-vascular endothelial growth factor use: the United States, the United kingdom, and Asia-Pacific","volume":"3","author":"Parikh","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"2025120618354399000_13.7.e067921.42","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.201129"},{"key":"2025120618354399000_13.7.e067921.43","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s10792-022-02261-1","article-title":"The efficacy of different anti-vascular endothelial growth factor agents and Prognostic biomarkers in monitoring of the treatment for myopic Choroidal neovascularization","volume":"42","author":"Karasu","year":"2022","journal-title":"Int Ophthalmol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-067921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T02:35:56Z","timestamp":1765074956000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-067921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,20]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/bmjopen-2022-067921"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-067921","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}